person · Reporting owner
Johnson David Michael
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aura Biosciences, Inc.AURA · Entity 5142 | Director | June 11, 2026 | June 15, 2026 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Director | June 16, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aura Biosciences, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 194,167 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 15,000 · Balance 194,167 F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.21 · Expires 2036-06-11 | Direct | 30,000 |
Reported balance
After 2026-06-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-06-11 · Grant · Acquired 30,000 · Balance 30,000 F5: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy NEJ09 IRREVOCABLE TRUST | 75,000 |
Reported balance
Holding disclosure · report date 2026-06-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 75,000 F2: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy NEJ12 IRREVOCABLE TRUST | 75,000 |
Reported balance
Holding disclosure · report date 2026-06-11 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 75,000 F3: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy Velocity Capital Management | 139,672 |
Reported balance
Holding disclosure · report date 2026-06-11 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 139,672 F4: Velosity Capital Management LLC is an entity that the Reporting Person is the sole member of. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.
F2: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee.
F3: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee.
F4: Velosity Capital Management LLC is an entity that the Reporting Person is the sole member of.
F5: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date.
Zentalis Pharmaceuticals, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 307,521 |
Reported balance
After 2026-06-16 transaction · row 1
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 57,100 · Balance 307,521 F1: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 20:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 57,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001808098-26-000003 · wk-form4_1781813348.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 307,521 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:30 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0001193125-26-271168 · ownership.xml · derivative · entry 5 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2036-06-11 F5 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:30 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-271168 · ownership.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 194,167 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 11, 2027 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 57,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-25-000133 · wk-form4_1750277742.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,421 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 17, 2026 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:10 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $6.18 | $0.00 |
DisclosureSEC source: 0000950170-25-087890 · ownership.xml · derivative · entry 5 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2035-06-17 F5 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 17, 2026 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 20:10 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-087890 · ownership.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,167 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 17, 2026 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. Read SEC document |
| May 16, 2025 Filed May 20, 2025 21:43 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock Warrants (right to buy) · Derivative | 5,000 | Not disclosed Strike: $4.90 | Not disclosed |
DisclosureSEC source: 0000950170-25-075412 · ownership.xml · derivative · entry 5 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-05-16 F1 · kind: On May 16, 2025, the Reporting Person purchased 20,000 shares of the Issuer's common stock and a warrant to purchase 5,000 shares of the Issuer's common stock at a purchase price of $4.90 in an underwritten public offering. F1 · price: On May 16, 2025, the Reporting Person purchased 20,000 shares of the Issuer's common stock and a warrant to purchase 5,000 shares of the Issuer's common stock at a purchase price of $4.90 in an underwritten public offering. Read SEC document |
| May 16, 2025 Filed May 20, 2025 21:43 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 20,000 | $4.90 | $98,000.00 |
DisclosureSEC source: 0000950170-25-075412 · ownership.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,167 F1 · kind: On May 16, 2025, the Reporting Person purchased 20,000 shares of the Issuer's common stock and a warrant to purchase 5,000 shares of the Issuer's common stock at a purchase price of $4.90 in an underwritten public offering. Read SEC document |
| June 21, 2024 Filed Jun 21, 2024 21:07 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 48,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-24-000141 · wk-form4_1719004045.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,818 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 21, 2025 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:05 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $6.93 | $0.00 |
DisclosureSEC source: 0000950170-24-076707 · ownership.xml · derivative · entry 5 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2034-06-20 F5 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 20, 2025 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:05 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantCommon Stock | 10,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076707 · ownership.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,167 F1 · shares: These shares were acquired pursuant to a restricted stock unit ("RSU") award under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the right to receive one share of the Issuer's Common Stock. These RSUs vest in full upon the earlier to occur of (a) June 20, 2025 or (b) the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service as of such vesting date. Read SEC document |
| November 10, 2023 Filed Nov 13, 2023 22:24 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | PurchaseCommon Stock | 17,000 | $9.88 | $167,943.00 |
DisclosureSEC source: 0001725160-23-000201 · wk-form4_1699914237.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,389 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.70 to $9.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2023 Filed Nov 9, 2023 22:02 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 10,000 | $7.30 | $73,000.00 |
DisclosureSEC source: 0000950170-23-062214 · ownership.xml · nonDerivative · entry 6 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By NEJ12 IRREVOCABLE TRUST Disclosed balance after: 75,000 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $7.22 to $7.42, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| November 08, 2023 Filed Nov 9, 2023 22:02 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 10,000 | $7.30 | $73,000.00 |
DisclosureSEC source: 0000950170-23-062214 · ownership.xml · nonDerivative · entry 5 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By NEJ09 IRREVOCABLE TRUST Disclosed balance after: 75,000 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $7.22 to $7.42, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. F2 · ownership.nature: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| November 08, 2023 Filed Nov 9, 2023 22:02 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 9,601 | $7.30 | $70,087.30 |
DisclosureSEC source: 0000950170-23-062214 · ownership.xml · nonDerivative · entry 4 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 135,667 F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $7.22 to $7.42, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 22:02 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 47,000 | $7.17 | $336,990.00 |
DisclosureSEC source: 0000950170-23-062214 · ownership.xml · nonDerivative · entry 3 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By NEJ09 IRREVOCABLE TRUST Disclosed balance after: 65,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $6.50 to $7.42, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. F3 · ownership.nature: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 22:02 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 47,000 | $7.17 | $336,990.00 |
DisclosureSEC source: 0000950170-23-062214 · ownership.xml · nonDerivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By NEJ09 IRREVOCABLE TRUST Disclosed balance after: 65,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $6.50 to $7.42, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. F2 · ownership.nature: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 22:02 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 76,000 | $7.17 | $544,920.00 |
DisclosureSEC source: 0000950170-23-062214 · ownership.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,066 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $6.50 to $7.42, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 04, 2023 Filed Oct 5, 2023 23:56 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 6,566 | $8.61 | $56,512.25 |
DisclosureSEC source: 0000950170-23-052244 · ownership.xml · nonDerivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,066 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $8.52 to $8.66, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 23:56 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 13,500 | $8.27 | $111,662.55 |
DisclosureSEC source: 0000950170-23-052244 · ownership.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,500 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions in prices ranging from $8.00 to $8.51, inclusive. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 16, 2023 Filed Jun 16, 2023 21:04 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 19,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-23-000146 · wk-form4_1686949452.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,389 F1 · shares: Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2024 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:56 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $12.83 | $0.00 |
DisclosureSEC source: 0000899243-23-015206 · doc4.xml · derivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2033-06-07 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 7, 2024 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 22:55 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 904 | $10.51 | $9,501.04 |
DisclosureSEC source: 0000899243-23-001324 · doc4.xml · nonDerivative · entry 4 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ12 IRREVOCABLE TRUST Disclosed balance after: 18,000 F2 · ownership.nature: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| January 06, 2023 Filed Jan 9, 2023 22:55 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 700 | $10.50 | $7,350.00 |
DisclosureSEC source: 0000899243-23-001324 · doc4.xml · nonDerivative · entry 3 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ09 IRREVOCABLE TRUST Disclosed balance after: 18,000 F1 · ownership.nature: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 22:55 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 96 | $10.00 | $960.00 |
DisclosureSEC source: 0000899243-23-001324 · doc4.xml · nonDerivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ12 IRREVOCABLE TRUST Disclosed balance after: 17,096 F2 · ownership.nature: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 22:55 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 300 | $10.00 | $3,000.00 |
DisclosureSEC source: 0000899243-23-001324 · doc4.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ09 IRREVOCABLE TRUST Disclosed balance after: 17,300 F1 · ownership.nature: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| December 28, 2022 Filed Dec 31, 2022 00:01 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 2,000 | $9.75 | $19,500.00 |
DisclosureSEC source: 0000899243-22-039594 · doc4.xml · nonDerivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ12 IRREVOCABLE TRUST Disclosed balance after: 17,000 F2 · ownership.nature: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| December 28, 2022 Filed Dec 31, 2022 00:01 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 2,000 | $9.75 | $19,500.00 |
DisclosureSEC source: 0000899243-22-039594 · doc4.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ09 IRREVOCABLE TRUST Disclosed balance after: 17,000 F1 · ownership.nature: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| December 01, 2022 Filed Dec 15, 2022 23:15 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 5,000 | $12.37 | $61,850.00 |
DisclosureSEC source: 0000899243-22-038695 · doc4.xml · nonDerivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ12 IRREVOCABLE TRUST Disclosed balance after: 15,000 F2 · ownership.nature: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| December 01, 2022 Filed Dec 15, 2022 23:15 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 5,000 | $12.37 | $61,850.00 |
DisclosureSEC source: 0000899243-22-038695 · doc4.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ09 IRREVOCABLE TRUST Disclosed balance after: 15,000 F1 · ownership.nature: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 21:07 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 16,000 | $0.00 Strike: $13.72 | $0.00 |
DisclosureSEC source: 0000899243-22-023128 · doc4.xml · derivative · entry 5 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2032-06-15 F4 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 15, 2023 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 01:29 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 20,000 | $13.99 | $279,800.00 |
DisclosureSEC source: 0000899243-22-022456 · doc4.xml · nonDerivative · entry 6 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 01:29 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 7,000 | $13.99 | $97,930.00 |
DisclosureSEC source: 0000899243-22-022456 · doc4.xml · nonDerivative · entry 5 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ12 IRREVOCABLE TRUST Disclosed balance after: 10,000 F2 · ownership.nature: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 01:29 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 7,000 | $13.99 | $97,930.00 |
DisclosureSEC source: 0000899243-22-022456 · doc4.xml · nonDerivative · entry 4 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ09 IRREVOCABLE TRUST Disclosed balance after: 10,000 F1 · ownership.nature: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| June 10, 2022 Filed Jun 15, 2022 01:29 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 10,000 | $15.04 | $150,400.00 |
DisclosureSEC source: 0000899243-22-022456 · doc4.xml · nonDerivative · entry 3 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| June 10, 2022 Filed Jun 15, 2022 01:29 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 3,000 | $15.04 | $45,120.00 |
DisclosureSEC source: 0000899243-22-022456 · doc4.xml · nonDerivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ12 IRREVOCABLE TRUST Disclosed balance after: 3,000 F2 · ownership.nature: The shares are held by the NEJ12 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| June 10, 2022 Filed Jun 15, 2022 01:29 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | PurchaseCommon Stock | 3,000 | $15.04 | $45,120.00 |
DisclosureSEC source: 0000899243-22-022456 · doc4.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By NEJ09 IRREVOCABLE TRUST Disclosed balance after: 3,000 F1 · ownership.nature: The shares are held by the NEJ09 IRREVOCABLE TRUST dated December 24, 2020, of which the Reporting Person is a trustee. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:22 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 24,871 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-22-000121 · wf-form4_165489251364998.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,330 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 8, 2023 or (b) the next occurring annual meeting of the Company's stockholders, subject to the Reporting Person's continued service on the Board of Directors through such vesting date. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 20:11 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | ConversionSeries E Convertible Preferred Stock · Derivative | 139,672 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-042361 · doc4.xml · derivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Velocity Capital Management LLC Disclosed balance after: 0 Underlying: Common Stock · 139,672 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series E Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · price: The Series E Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · derivative.exercise_date: The Series E Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F1 · derivative.expiration_date: The Series E Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F2 · ownership.nature: Velosity Capital Management LLC is an entity that the reporting person is the sole member of. Read SEC document |
| November 02, 2021 Filed Nov 2, 2021 20:11 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | ConversionCommon Stock | 139,672 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042361 · doc4.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Velocity Capital Management Disclosed balance after: 139,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The Series E Preferred Stock converted into the number of shares of Common Stock of the Issuer upon the closing of the Issuer's Initial Public Offering. These amounts reflect a 1-for-13.700 reverse split which became effective on October 22, 2021. F2 · ownership.nature: Velosity Capital Management LLC is an entity that the reporting person is the sole member of. Read SEC document |
| October 28, 2021 Filed Oct 29, 2021 23:33 UTC | Aura Biosciences, Inc. AURA · Entity 5142 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042095 · doc4.xml · derivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2031-10-27 F1 · derivative.exercise_date: The shares underlying this option vest as follows: These shares will vest in full on October 28, 2022. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 01:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 100 | $67.20 | $6,720.00 |
DisclosureSEC source: 0001725160-21-000197 · wf-form4_163339649177277.xml · nonDerivative · entry 3 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,959 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 01:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 7,904 | $66.58 | $526,240.42 |
DisclosureSEC source: 0001725160-21-000197 · wf-form4_163339649177277.xml · nonDerivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,059 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $66.16 to $67.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 01:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,892 | $65.95 | $322,627.89 |
DisclosureSEC source: 0001725160-21-000197 · wf-form4_163339649177277.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,963 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $65.16 to $66.15. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 21:26 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $52.25 | $0.00 |
DisclosureSEC source: 0001725160-21-000142 · wf-form4_162318757634162.xml · derivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-03 F2 · derivative.exercise_date: The option vests and become exercisable in substantially equal monthly installments over the twelve (12) months following the date of grant, subject to the Reporting Person's continued service on the Board of Directors through each such vesting date. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 21:26 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000142 · wf-form4_162318757634162.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,855 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 4, 2022 or (b) the next occurring annual meeting of the Company's stockholders, subject to the Reporting Person's continued service on the Board of Directors through such vesting date. Read SEC document |
| June 04, 2021 Filed Dec 17, 2021 22:57 UTC Amendment | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $52.25 | $0.00 |
DisclosureSEC source: 0001725160-21-000242 · wf-form4a_163978182697479.xml · derivative · entry 2 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2031-06-03 F3 · shares: This amendment is being filed to correct the number of stock options granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted 22,500 options on June 4, 2021. The options vest and become exercisable in substantially equal monthly installments over the twelve (12) months following the date of grant, subject to the Reporting Person's continued service on the Board of Directors through each such vesting date. F3 · derivative.exercise_date: This amendment is being filed to correct the number of stock options granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted 22,500 options on June 4, 2021. The options vest and become exercisable in substantially equal monthly installments over the twelve (12) months following the date of grant, subject to the Reporting Person's continued service on the Board of Directors through each such vesting date. F3 · derivative.underlying_shares: This amendment is being filed to correct the number of stock options granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted 22,500 options on June 4, 2021. The options vest and become exercisable in substantially equal monthly installments over the twelve (12) months following the date of grant, subject to the Reporting Person's continued service on the Board of Directors through each such vesting date. F3 · balance_after: This amendment is being filed to correct the number of stock options granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted 22,500 options on June 4, 2021. The options vest and become exercisable in substantially equal monthly installments over the twelve (12) months following the date of grant, subject to the Reporting Person's continued service on the Board of Directors through each such vesting date. Read SEC document |
| June 04, 2021 Filed Dec 17, 2021 22:57 UTC Amendment | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000242 · wf-form4a_163978182697479.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,355 F1 · shares: This amendment is being filed to correct the number of RSUs granted to the Reporting Person, which was inadvertently understated on the Reporting Person's original Form 4. The Reporting Person was granted 7,500 RSUs on June 4, 2021, to vest on the first to occur of (a) June 4, 2022 or (b) the next occurring annual meeting of the Company's stockholders. F2 · balance_after: Due to the error described above, the Reporting Person's Form 4 filed on October 4, 2021 incorrectly reported that the number of shares held by the Reporting Person was 80,959 shares of Common Stock. Read SEC document |
| April 05, 2021 Filed Apr 5, 2021 23:54 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 12,897 | $43.50 | $561,020.79 |
DisclosureSEC source: 0001725160-21-000079 · wf-form4_161766675973088.xml · nonDerivative · entry 1 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,855 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. Read SEC document |
| December 02, 2020 Filed Dec 3, 2020 22:57 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,825 | $52.72 | $148,934.00 |
DisclosureSEC source: 0001725160-20-000052 · wf-form4_160703623563271.xml · nonDerivative · entry 5 Johnson David Michael · CIK 0001808098 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,752 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2020. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.39 to $53.21. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.